<DOC>
	<DOCNO>NCT00266630</DOCNO>
	<brief_summary>The efficacy safety extend treatment patient recent episode manic mixed complete previous double blind study ( F1D-JE-BMAC [ Study BMAC ] ) examine .</brief_summary>
	<brief_title>Efficacy Safety Olanzapine Extended Treatment Manic Mixed Episode Bipolar I Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Valproic Acid</mesh_term>
	<mesh_term>Carbamazepine</mesh_term>
	<mesh_term>Lithium Carbonate</mesh_term>
	<mesh_term>Olanzapine</mesh_term>
	<criteria>Enrolled complete Study BMAC ( NCT00129220 ) , discontinue Study BMAC Visit 4 Visit 5 due lack efficacy Young Mania Rating Scale ( YMRS ) total score time discontinuation low baseline Study BMAC Are diagnose `` 294.4x Bipolar I Disorder , Most Recent Episode Manic '' `` 296.6x Bipolar I Disorder , Most Recent Episode Mixed , '' determine MiniInternational Neuropsychiatric Interview ( MINI ) Have diagnosis diabetes mellitus Significant protocol deviation Study BMAC The actual date final visit Study BMAC 4 day later schedule date first visit Study BMEX</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2010</verification_date>
</DOC>